TRVI
Trevi Therapeutics, Inc.
$14.50
+3.20%
2026-05-08
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Key Fundamentals
Forward P/E
-26.51
EPS (TTM)
$-0.32
ROE
-33.6%
Profit Margin
0.0%
Debt/Equity
0.40
Price/Book
10.15
Beta
1.08
Market Cap
$2.06B
Avg Volume (10D)
1.6M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$16.12
60D Low
$9.82
Avg Volume
1.5M
Latest Close
$14.50
Get breakout alerts for TRVI
Sign up for Breakout Scanner to receive daily notifications when TRVI triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Trevi Therapeutics, Inc. (TRVI) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors TRVI daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. TRVI operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.